Avandia Panelist Issue Sent To HHS Inspector General

By Jacqueline Bell (July 27, 2010, 1:48 PM EDT) -- The U.S. Food and Drug Administration has asked the inspector general of the Department of Health and Human Services to look into concerns that one of its advisory panelists who voted to keep the controversial diabetes drug Avandia on the market is also a paid speaker for the drug's manufacturer....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!